News
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
17hon MSN
RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...
Vaccination was cost saving for participants aged 65 years and older. In phase 2 analyses, an additional dose was ...
German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...
In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...
15h
Barchart on MSNModerna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here?Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...
HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results